143 related articles for article (PubMed ID: 16298299)
1. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin.
David-Cordonnier MH; Gajate C; Olmea O; Laine W; de la Iglesia-Vicente J; Perez C; Cuevas C; Otero G; Manzanares I; Bailly C; Mollinedo F
Chem Biol; 2005 Nov; 12(11):1201-10. PubMed ID: 16298299
[TBL] [Abstract][Full Text] [Related]
2. The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.
Erba E; Cavallaro E; Damia G; Mantovani R; Di Silvio A; Di Francesco AM; Riccardi R; Cuevas C; Faircloth GT; D'Incalci M
Oncol Res; 2004; 14(11-12):579-87. PubMed ID: 15666999
[TBL] [Abstract][Full Text] [Related]
3. DNA structural similarity in the 2:1 complexes of the antitumor drugs trabectedin (Yondelis) and chromomycin A3 with an oligonucleotide sequence containing two adjacent TGG binding sites on opposing strands.
Marco E; Gago F
Mol Pharmacol; 2005 Dec; 68(6):1559-67. PubMed ID: 16150929
[TBL] [Abstract][Full Text] [Related]
4. Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis.
Gajate C; An F; Mollinedo F
J Biol Chem; 2002 Nov; 277(44):41580-9. PubMed ID: 12198119
[TBL] [Abstract][Full Text] [Related]
5. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent.
Zewail-Foote M; Li VS; Kohn H; Bearss D; Guzman M; Hurley LH
Chem Biol; 2001 Nov; 8(11):1033-49. PubMed ID: 11731295
[TBL] [Abstract][Full Text] [Related]
6. Increased DNA binding specificity for antitumor ecteinascidin 743 through protein-DNA interactions?
García-Nieto R; Manzanares I; Cuevas C; Gago F
J Med Chem; 2000 Nov; 43(23):4367-9. PubMed ID: 11087561
[No Abstract] [Full Text] [Related]
7. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
van Kesteren Ch; de Vooght MM; López-Lázaro L; Mathôt RA; Schellens JH; Jimeno JM; Beijnen JH
Anticancer Drugs; 2003 Aug; 14(7):487-502. PubMed ID: 12960733
[TBL] [Abstract][Full Text] [Related]
8. A review of trabectedin (ET-743): a unique mechanism of action.
D'Incalci M; Galmarini CM
Mol Cancer Ther; 2010 Aug; 9(8):2157-63. PubMed ID: 20647340
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.
Martínez N; Sánchez-Beato M; Carnero A; Moneo V; Tercero JC; Fernández I; Navarrete M; Jimeno J; Piris MA
Mol Cancer Ther; 2005 May; 4(5):814-23. PubMed ID: 15897246
[TBL] [Abstract][Full Text] [Related]
10. New drugs from the sea.
D'Incalci M; Simone M; Tavecchio M; Damia G; Garbi A; Erba E
J Chemother; 2004 Nov; 16 Suppl 4():86-9. PubMed ID: 15688619
[TBL] [Abstract][Full Text] [Related]
11. In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction.
Brandon EF; Meijerman I; Klijn JS; den Arend D; Sparidans RW; Lázaro LL; Beijnen JH; Schellens JH
Anticancer Drugs; 2005 Oct; 16(9):935-43. PubMed ID: 16162970
[TBL] [Abstract][Full Text] [Related]
12. Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: new molecular insight into the mechanism of action.
Martínez-Serra J; Maffiotte E; Martín J; Bex T; Navarro-Palou M; Ros T; Plazas JM; Vögler O; Gutiérrez A; Amat JC; Ramos R; Saus C; Ginés J; Alemany R; Diaz M; Besalduch J
Eur J Pharmacol; 2011 May; 658(2-3):57-64. PubMed ID: 21371453
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650.
Martinez EJ; Corey EJ; Owa T
Chem Biol; 2001 Dec; 8(12):1151-60. PubMed ID: 11755394
[TBL] [Abstract][Full Text] [Related]
14. Hepatotoxicity and metabolism of trabectedin: a literature review.
Beumer JH; Schellens JH; Beijnen JH
Pharmacol Res; 2005 May; 51(5):391-8. PubMed ID: 15749453
[TBL] [Abstract][Full Text] [Related]
15. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).
Romano M; Frapolli R; Zangarini M; Bello E; Porcu L; Galmarini CM; García-Fernández LF; Cuevas C; Allavena P; Erba E; D'Incalci M
Int J Cancer; 2013 Nov; 133(9):2024-33. PubMed ID: 23588839
[TBL] [Abstract][Full Text] [Related]
16. Trabectedin is a promising antitumour agent for synovial sarcoma.
Yasui H; Imura Y; Outani H; Hamada K; Nakai T; Yamada S; Takenaka S; Sasagawa S; Araki N; Itoh K; Myoui A; Yoshikawa H; Naka N
J Chemother; 2016 Oct; 28(5):417-24. PubMed ID: 27077926
[TBL] [Abstract][Full Text] [Related]
17. The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin.
D'Angelo D; Borbone E; Palmieri D; Uboldi S; Esposito F; Frapolli R; Pacelli R; D'Incalci M; Fusco A
Eur J Cancer; 2013 Mar; 49(5):1142-51. PubMed ID: 23149213
[TBL] [Abstract][Full Text] [Related]
18. Further insight into the DNA recognition mechanism of trabectedin from the differential affinity of its demethylated analogue ecteinascidin ET729 for the triplet DNA binding site CGA.
Marco E; David-Cordonnier MH; Bailly C; Cuevas C; Gago F
J Med Chem; 2006 Nov; 49(23):6925-9. PubMed ID: 17154523
[TBL] [Abstract][Full Text] [Related]
19. Differential rates of reversibility of ecteinascidin 743-DNA covalent adducts from different sequences lead to migration to favored bonding sites.
Zewail-Foote M; Hurley LH
J Am Chem Soc; 2001 Jul; 123(27):6485-95. PubMed ID: 11439034
[TBL] [Abstract][Full Text] [Related]
20. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin.
Herrero AB; Martín-Castellanos C; Marco E; Gago F; Moreno S
Cancer Res; 2006 Aug; 66(16):8155-62. PubMed ID: 16912194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]